Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2023
Conference Publication
Factors that influence clinical trial participation for oncology patients in Australia: A scoping review
You, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth Stephanie, Roberts, Natasha Anne and Wyld, David (2023). Factors that influence clinical trial participation for oncology patients in Australia: A scoping review. 2023 ASCO Quality Care Symposium, Boston, MA United States, 27-28 October 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/op.2023.19.11_suppl.111
2023
Journal Article
The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis
Guccione, Lisa, Gough, Karla, Drosdowsky, Allison, Price, Timothy, Pavlakis, Nick, Wyld, David, Ransom, David, Michael, Michael and Schofield, Penelope (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer, 31 (10) 577, 1-11. doi: 10.1007/s00520-023-08034-5
2023
Journal Article
Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort study
Scanlon, Brighid, Durham, Jo, Wyld, David, Roberts, Natasha and Toloo, Ghasem Sam (2023). Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort study. International Journal for Equity in Health, 22 (1) 175, 1-10. doi: 10.1186/s12939-023-01957-9
2023
Conference Publication
An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102
2023
Journal Article
Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer
Lee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091
2023
Conference Publication
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Journal Article
Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patients
Scanlon, Brighid, Wyld, David, Roberts, Natasha, Durham, Jo and Toloo, Ghasem (Sam) (2023). Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patients. Global Public Health, 18 (1) 2202213, 1-13. doi: 10.1080/17441692.2023.2202213
2023
Journal Article
Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)
Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848
2023
Conference Publication
PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma
Pattison, D. A., Kong, G., Hofman, M. S., Akhurst, T., Ravi, Kumar A. S., Michael, M., Wyld, D., Burge, M., Chiang, C., Sachithanandan, N., Love, A. and Hicks, R. (2023). PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma. 20th Annual ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, Mar 22-24, 2023. HOBOKEN: WILEY.
2023
Conference Publication
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431
2023
Conference Publication
P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Journal Article
Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionals
Joseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa and Chan, Raymond J. (2023). Essential elements of optimal dietary and exercise referral practices for cancer survivors: expert consensus for medical and nursing health professionals. Supportive Care in Cancer, 31 (1) 46, 1-14. doi: 10.1007/s00520-022-07509-1
2022
Journal Article
COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey
Scanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2022). COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 47 (1), 110-118. doi: 10.1071/ah22142
2022
Conference Publication
Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionals
Joseph, Ria, Hart, Nicolas H., Bradford, Natalie, Wallen, Matthew P., Han, Chad Y., Pinkham, Elizabeth P., Hanley, Brigid, Lock, Gemma, Wyld, David, Wishart, Laurelie, Koczwara, Bogda, Chan, Alexandre, Agbejule, Oluwaseyifunmi Andi, Crichton, Megan, Teleni, Laisa, Holland, Justin J., Edmiston, Kelli, Naumann, Leonie, Brown, Teresa and Chan, Raymond J. (2022). Essential elements of optimal dietary and exercise referral practices for cancer survivors: Expert consensus for medical and nursing health professionals. HOBOKEN: WILEY.
2022
Conference Publication
P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869
2022
Conference Publication
Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting
Kim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY.
2022
Conference Publication
Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, Australia
Moorhead, William, Youl, Philippa, Moore, Julie and Wyld, David (2022). Appendiceal neuroendocrine tumours in individuals under the age of 50 years: A population-based study from Queensland, Australia. HOBOKEN: WILEY.
2022
Conference Publication
Factors that influence cancer clinical trials participation in Australia: A scoping review
You, Kyung Ha (Kathy), Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2022). Factors that influence cancer clinical trials participation in Australia: A scoping review. HOBOKEN: WILEY.
2022
Conference Publication
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results
Pavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2022
Conference Publication
Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors
Hoe, Hui Jing and Wyld, David (2022). Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Associate Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: